Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lotus Pharmaceutical CoTPE:1795 +0.77%75 EV-to-EBITDA is 9.49 as of Aug. 26, 2026, which is 26% below its 10-year median of 12.90. GuruFocus rates TPE:1795 with a GF Score™ of 75/100 and a GF Value™ of NT$460.86 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 735 Drug Manufacturers companies, Lotus Pharmaceutical Co ranks better than 62.99% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Lotus Pharmaceutical Co's enterprise value is NT$94,854 Mil.
Lotus Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$9,999 Mil. Therefore, Lotus Pharmaceutical Co's EV-to-EBITDA for today is 9.49.
The historical rank and industry rank for Lotus Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:
TPE:1795'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.15 Med: 12.9 Max: 40.56
Current: 9.49
During the past 13 years, the highest EV-to-EBITDA of Lotus Pharmaceutical Co was 40.56. The lowest was 7.15. And the median was 12.90.
TPE:1795's EV-to-EBITDA is ranked better than 62.99% of 735
companies
in the Drug Manufacturers industry
Industry Median: 13.07
vs TPE:1795: 9.49
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Lotus Pharmaceutical Co (TPE:1795) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lotus Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Lotus Pharmaceutical Co's share price for today is NT$195.50.
Lotus Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$14.410.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lotus Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lotus Pharmaceutical Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lotus Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Lotus Pharmaceutical Co's EV-to-EBITDA falls into.
Lotus Pharmaceutical Co's current Enterprise Value is NT$94,854 Mil.
Lotus Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$9,999 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lotus Pharmaceutical Co (TPE:1795) has a EV-to-EBITDA of 9.49 as of Aug. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Lotus Pharmaceutical Co. This is 26% below median its historical median of 12.90. Over the past decade, Lotus Pharmaceutical Co's EV-to-EBITDA has ranged from 7.15 to 40.56. According to the industry distribution chart, Lotus Pharmaceutical Co ranks #272 out of 735 companies in the Drug Manufacturers industry, placing it in the top 37%.
Is Lotus Pharmaceutical Co's EV-to-EBITDA too high?
Lotus Pharmaceutical Co's current EV-to-EBITDA of 9.49 is 26% below median its 10-year median of 12.90. Over the past 10 years, this metric has ranged from a low of 7.15 to a high of 40.56. The Drug Manufacturers industry median EV-to-EBITDA is 13.07. Lotus Pharmaceutical Co's value of 9.49 is 27.4% below this industry median. Based on the distribution chart, Lotus Pharmaceutical Co ranks #272 out of 735 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Lotus Pharmaceutical Co has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lotus Pharmaceutical Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Lotus Pharmaceutical Co ranks #272 out of 735 companies for EV-to-EBITDA. This puts Lotus Pharmaceutical Co in the upper half of its industry. The industry median EV-to-EBITDA is 13.07. Lotus Pharmaceutical Co's value of 9.49 is 27.4% below this benchmark. Historically, Lotus Pharmaceutical Co's own EV-to-EBITDA has ranged from 7.15 to 40.56 over the past decade. While the company's 10-year median is 12.90 vs. the industry median of 13.07, Lotus Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.07, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lotus Pharmaceutical Co's current EV-to-EBITDA of 9.49 is 27.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Lotus Pharmaceutical Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lotus Pharmaceutical Co's current EV-to-EBITDA is 9.49, which is 26% below median its own 10-year median of 12.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lotus Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Lotus Pharmaceutical Co (TPE:1795) is currently considered Possible Value Trap. The stock's GF Value™ is NT$460.86, compared to a current price of NT$195.50 — trading 57.6% below its estimated fair value. The current EV-to-EBITDA is 9.49, which is 26% below median its 10-year median of 12.90 and 27.4% below the Drug Manufacturers industry median of 13.07. Lotus Pharmaceutical Co's overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Lotus Pharmaceutical Co (TPE:1795), the current EV-to-EBITDA is 9.49 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lotus Pharmaceutical Co (TPE:1795) Overvalued in 2026?
Based on GuruFocus' analysis, Lotus Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$195.50 is trading 57.6% below its estimated GF Value™ of NT$460.86.
GuruFocus considers Lotus Pharmaceutical Co to be Possible Value Trap.
Key valuation signals for TPE:1795:
EV-to-EBITDA: 9.49 (26% below median its 10-year median of 12.90)
GF Value™: NT$460.86 vs. price of NT$195.50 (57.6% below fair value)
Industry Position: 27.4% below the Drug Manufacturers median (#272 of 735)
No single metric tells the full story. See the TPE:1795 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. Along with its subsidiaries, it is engaged in the research and development, manufacturing, and sales of generic and branded pharmaceutical products, as well as consulting services. Its product portfolio comprises biosimilars, generic medicines, branded medicines, and various therapies in its research and development pipeline. The Group offers a differentiated portfolio of pharmaceuticals spanning several therapeutic areas, including oncology and immunology, CNS, women's health, primary care and lifestyle, and nephrology, among others. Geographically, it generates maximum revenue from the United States, and the rest from Taiwan, South Korea, Singapore, and other countries.
75GF Score
Get the complete analysis for TPE:1795
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1795 has been successfully added to your 
